The objectives of this study are to establish the performance characteristics of the AC2 (APTIMA Combo 2) Assay on the PANTHER System for the sample types cleared for use on the TIGRIS and DTS (Direct Tube Sampling) Systems and to demonstrate the repeatability and reproducibility of the AC2 Assay on the PANTHER System.
The results of this protocol AC2PS-US11-001 (NCT01733069) are based on samples collected from protocol ACTPS-US10-001(NCT01358799). The registration for NCT01358799 was withdrawn because the samples were not tested under protocol ACTPS-US10-001, instead they were tested under the protocol registered here AC2PS-US11-001 (NCT01733069).
Study Type
OBSERVATIONAL
Enrollment
1,912
APTIMA COMBO 2 Assay (AC2 Assay
Wishard Health Services Department of Pathology Wishard Health Services
Indianapolis, Indiana, United States
Louisiana State University Health Center
New Orleans, Louisiana, United States
New England Center for Clinical Research
Fall River, Massachusetts, United States
APTIMA Combo 2 Assay Accuracy Compared to Infected Status by Sample Type
Count of participants having a positive or negative APTIMA Combo 2 assay result (sensitivity and specificity)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of North Carolina Chapel Hill STD Clinic
Chapel Hill, North Carolina, United States
Planned Parenthood Northeast Ohio
Akron, Ohio, United States
Cincinnati Children's Hospital Medical Center Division of Pediatric & Adolescent Gynecology
Cincinnati, Ohio, United States
Planned Parenthood Houston and Southeast Texas
Houston, Texas, United States